X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
The collaboratin aims to evaluate the investigational cereblon E3 ligase modulator agent mezigdomide in combination with Karyopharm's selinexor, an approved first-in-class inhibitor of XPO1, plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Lead Product(s): Mezigdomide,Selinexor
Therapeutic Area: Oncology Product Name: BMS-986348
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 30, 2023
Details:
Under the agreement, Hansoh will be exclusively responsible for commercialization of Xpovio (selinexor), world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1, in the mainland of China for relapsed or refractory multiple myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $101.5 million Upfront Cash: $27.6 million
Deal Type: Collaboration August 10, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of selective Inhibitor of Nuclear Export (SINE) compounds which down-regulates the levels of multiple oncogenic proteins, being developed for the treatment of cancer.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and currently investigated in combination with ruxolitinib in JAKi-naïve patients with myelofibrosis.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export inhibitor approved by the Therapeutic Goods Administration of Australia for patients with relapsed and/or refractory multiple myeloma and in triple class refractory R/R MM.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of selective Inhibitor of Nuclear Export (SINE) compounds which down-regulates the levels of multiple oncogenic proteins, for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
Nexpovio (selinexor) reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2023
Details:
XPOVIO (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
NEXPOVIO (Selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor, functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
XPOVIO (selinexor) is an oral medicine used to treat adults with multiple myeloma or relapsed/refractory diffuse large B-cell lymphoma. Antengene has successfully transitioned to an innovative company with a pipeline of 15 novel, clinical and preclinical programs for oncology.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Encouraging initial data observed in phase 1/2 study of Nexpovio (selinexor) in combination with ruxolitinib in treatment-myelofibrosis, favorable tolerability with nodose-limitingg toxicities and 75% of evaluable patients demonstrating ≥35% spleen volume reduction at week 12.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
XPOVIO (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Myeloma Network
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
XPOVIO® (selinexor) is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Lead Product(s): Selinexor,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Nexpovio (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination with once weekly bortezomib and low-dose dexamethasone for treatment of adults with multiple myeloma who have received one to three prior lines of therapy.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Selinexor is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
XPOVIO® (Selinexor), world’s first oral selective inhibitor of nuclear export protein approved for combination use with dexamethasone for treatment of patients with Relapsed/Refractory Multiple Myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: XPOVIO
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
Details:
Xpovio (selinexor) is the first and only oral XPO1 inhibitor approved by U.S. Food and Drug Administration (FDA) for treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2022
Details:
Abstract highlights encouraging activity of XPOVIO (selinexor) plus low-dose dexamethasone combo in small group of heavily pre-treated patients multiple myeloma previously exposed to chimeric antigen receptor T-cell therapy within registrational MARCH study conducted in China.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2022
Details:
XPOVIO (Selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
NMRC received written guidance from the U.S. FDA in relation to clinical development pathway of the new drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
XPOVIO is a first-in-class, oral exportin 1 inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The Phase 3 SIENDO study (ENGOT-EN5/GOG-3055), evaluating the efficacy and safety of Nexpovio (selinexor) as maintenance therapy following chemotherapy in patients with advanced or recurrent endometrial cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
XPOVIO® is first new class SINE medicine, in combination with bortezomib and dexamethasone (XBd), for treatment of patients with multiple myeloma, and in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
Karyopharm plans to initiate a new placebo-controlled randomized study of selinexor, a XPO1 inhibitor, in Endometrial Cancer p53 wild-type population to support a future sNDA submission as current topline data from SIENDO Study.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Selinexor, oral exportin 1 (XPO1) inhibitor demonstrates statistically significant 50% improvement in median progression-free survival compared to placebo for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
Under the terms of the agreement, Menarini received exclusive rights to commercialize NEXPOVIO for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $277.5 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement December 21, 2021
Details:
The primary endpoints of the study include the maximum-tolerated dose (MTD) and recommended Phase II dose (RP2D) of ATG-008 (onatasertib) plus ATG-010 (selinexor) in patients with rrDLBCL.
Lead Product(s): Onatasertib,Selinexor
Therapeutic Area: Oncology Product Name: ATG-008
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: XPOVIO
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2021
Details:
XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell.
Lead Product(s): Selinexor,Pembrolizumab
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Details:
Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple solid tumor indications, including liposarcoma and endometrial cancer.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2021
Details:
For the study's primary endpoint, oral selinexor achieved an overall response rate of 26% and the trial therefore met its primary endpoint (n=123). Minimal response per IMWG criteria was observed in 16 (13%) patients and 48 patients (39%) had stable disease.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
Results from this study demonstrated potent in vitro and in vivo anti-tumor efficacy and synergy with the combination of ATG-010 and ATG-008, including strong synergistic activities in the triple-hit DLBCL cell line.
Lead Product(s): Selinexor,Onatasertib
Therapeutic Area: Oncology Product Name: ATG-010
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
The European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of multiple myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
Karyopharm intends to submit a second regulatory filing to the EMA based on the data from the confirmatory Phase 3 BOSTON study, which evaluated once-weekly NEXPOVIO in combination with once-weekly Velcade® and low-dose dexamethasone in patients with multiple myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
The NDA submission includes positive data from the pivotal STORM and SADAL studies, which both demonstrated significant and meaningful efficacy with a manageable safety profile for ATG-010 (selinexor, XPOVIO®).
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: ATG-010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2021
Details:
XPOVIO® is a first-in-class and only-in-class oral SINE compound, and now the first and only drug approved by FDA for use in both multiple myeloma and diffuse large B-cell lymphoma, discovered and developed by Karyopharm, is currently being developed by Antengene.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
XPOVIO® (selinexor, ATG-010) is a first-in-class and only-in-class oral selective inhibitor of nuclear export, developed by Antengene and Karyopharm Therapeutics Inc.
Lead Product(s): Selinexor,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: XPOVIO
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Improvement in Median PFS in Patients with Advanced Unresectable Dedifferentiated Liposarcoma Following at Least Two Prior Therapies.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Once-weekly regimen of XPOVIO and Velcade®, with low-dose dexamethasone (SVd) reduced the risk of disease progression or death by 30% and induced a higher rate of overall and deep responses compared to patients receiving a standard twice-weekly Velcade®.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Updated Results from the Pomalyst®, Kyprolis® and Revlimid® Arms of the Phase 1b/2 STOMP Study Evaluating XPOVIO in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Presented.
Lead Product(s): Selinexor,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Twice-Weekly XPOVIO® (selinexor) demonstrates a statistically significant reduction in the risk of disease progression or death compared to placebo. SEAL study met its primary endpoint of a statistically significant increase in progression-free survival (PFS).
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Encouraging Anti-Viral and Anti-Inflammatory Activity Demonstrated in a Subset of Patients in a Study of Low Dose Selinexor in Hospitalized Patients with Severe COVID-19.
Lead Product(s): Selinexor
Therapeutic Area: Infections and Infectious Diseases Product Name: Xpovio
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Proceeds from the Series C financing will be primarily used to fund the continuing clinical development of Antengene's robust pipeline of hematology and oncology therapies, expanding in-house R&D capabilities and strengthening the commercial infrastructures in APAC markets.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: ATG-010
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fidelity Management & Research Company
Deal Size: $97.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing July 21, 2020
Details:
FDA has accepted for filing its supplemental New Drug Application seeking approval for XPOVIO® (selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for multiple myeloma after at least one prior line of therapy.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
The Cooperative Research and Development Agreement will focus on advancing XPOVIO (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, which blocks the cellular protein XPO1.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 17, 2020
Details:
First patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients with newly diagnosed or recurrent glioblastoma (GBM).
Lead Product(s): Selinexor,Temozolomide,Radiation Therapy
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Combination of once-weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (svd) prolonged median progression-free survival by 47% compared to standard twice-weekly velcade® plus dexamethasone (Vd).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
sNDA is backed by the top-line results from the pivotal Phase 3 BOSTON study evaluating the combination of XPOVIO (selinexor), once-weekly Velcade® (bortezomib) and low-dose dexamethasone as a second line treatment for patients with relapsed or refractory multiple myeloma.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
Karyopharm and PROMETRIKA together will conduct the first randomized clinical trial for low-dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.
Lead Product(s): Selinexor
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
